Cyclophosphamide/dactinomycin/vincristineLack of efficacy

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2024年 / 2011卷 / 1期

关键词：

D O I：

10.1007/s40278-024-60375-9

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：140 / 140

相关论文

共 50 条

[31] Methylprednisolone/rituximab/vincristineLack of efficacy
Reactions Weekly, 2024, 2006 (1) : 410 - 410
[32] Cyclophosphamide/dactinomycin/vincristineHaematological toxicity: case report
Reactions Weekly, 2014, 1530 (1) : 78 - 78
[33] Cyclophosphamide/dactinomycin/vincristineVarious toxicities: case report
Reactions Weekly, 2023, 1985 (1) : 170 - 170
[34] Cyclophosphamide/Dactinomycin/VincristinePulmonary nocardiosis: case report
Reactions Weekly, 2024, 2024 (1) : 150 - 150
[35] Cyclophosphamide/dactinomycin/vincristineBladder rupture: case report
Reactions Weekly, 2022, 1906 (1) : 159 - 159
[36] Cyclophosphamide/dactinomycin/vincristineLeucopenia and thrombocytopenia: case report
Reactions Weekly, 2019, 1768 (1) : 119 - 119
[37] Rituximab/vincristineLack of efficacy: case report
Reactions Weekly, 2021, 1883 (1) : 325 - 325
[38] Ifosfamide/vincristineLack of efficacy: case report
Reactions Weekly, 2022, 1887 (1) : 371 - 371
[39] Bendamustine/VincristineLack of efficacy: case report
Reactions Weekly, 2024, 2036 (1) : 90 - 90
[40] Topotecan/vincristineLack of efficacy: case report
Reactions Weekly, 2022, 1925 (1) : 479 - 479

← 1 2 3 4 5 →